Treatment of L-DOPA-induced Dyskinesia in Parkinson’s Disease

Description:

 Repurposed antidepressant agents for treating levodopa-induced dyskinesia in Parkinson's disease  

 

Background:

Dopamine replacement therapy with L-DOPA remains the gold-standard treatment for the crippling movement disruptions affecting >10 million Parkinson’s Disease patients worldwide. However, L-DOPA therapies, especially after prolonged use, are associated with painful and disabling abnormal involuntary movements termed L-DOPA induced dyskinesia (LID), which affect nearly 90% of patients within 10 years of commencing treatment. An estimated >2 million Parkinson’s disease patients worldwide will exhibit extremely disruptive LID this year alone.



Given that L-DOPA remains the most effective Parkinson’s treatment option, substantial research has focused on addressing this problem, yet without much success in the translation to the clinical setting. Recently, amantadine has become the first drug to be repurposed and approved for LID mitigation, but has encountered roadblocks in the clinic, including limited efficacy and major side effects.

 

Technology Overview:  

Binghamton University Professor Christopher Bishop has developed a new method for treating LID in Parkinson’s disease, demonstrating for the first time the anti-dyskinetic potential of dual partial 5-HT1A agonist/SSRI agents, including the FDA-approved antidepressants vilazodone (Viibryd) and vortioxetine (Trintellix). The dual-activity antidepressants dramatically reduced LID and maintained these effects for several weeks without altering L-DOPA’s positive anti-parkinsonian effects.  

 

https://binghamton.technologypublisher.com/files/sites/nerve-cell-2213009_19202.jpg

 

Advantages:  

  • More effective than currently approved therapy;
  • Potent and stable response;
  • Reduced side effect profile;
  • FDA-approved compounds positioned for rapid repurposing;
  • Effective in prevention and treatment of LID in Parkinson’s patients.

 

 

Applications:  

Treatment of L-DOPA-induced dyskinesia in Parkinson’s disease patients.  

 

Intellectual Property Summary:

PCT application filed. 


Available for licensing. Seeking to develop and commercialize via license agreement and/or sponsored research with a company active in the area

 

Stage of Development:

  • Approved compounds;
  • Pre-clinical animal study results available.

 

Licensing Status

Available for licensing. Seeking to develop and commercialize via license agreement and/or sponsored research with a company active in the area.

 

 

 

 

 

Patent Information:
For Information, Contact:
Olga Petrova
Binghamton University
opetrova@binghamton.edu
Inventors:
Christopher Bishop
Keywords:
#SUNYresearch
#SUNYresearch
Technologies
XCEED
© 2024. All Rights Reserved. Powered by Inteum